Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector *Anopheles darlingi*

Kevin C. Kobylinski1,2*, Karín S. Escobedo-Vargas3, Victor M. López-Sifuentes3, Salomón Durand4, Edward S. Smith4, G. Christian Baldeviano4, Robert V. Gerbasi5, Sara-Blythe Ballard6, Craig A. Stoops3 and Gissella M. Vásquez3

**Abstract**

**Background:** Outdoor malaria transmission hinders malaria elimination efforts in the Amazon region and novel vector control tools are needed. Ivermectin mass drug administration (MDA) to humans kills wild *Anopheles*, targets outdoor-feeding vectors, and can suppress malaria parasite transmission. Laboratory investigations were performed to determine ivermectin susceptibility, sporontocidal effect and inhibition of time to re-feed for the primary Amazonian malaria vector, *Anopheles darlingi*.

**Methods:** To assess ivermectin susceptibility, various concentrations of ivermectin were mixed in human blood and fed to *An. darlingi*. Mosquito survival was monitored daily for 7 days and a non-linear mixed effects model with Probit analysis was used to calculate lethal concentrations of ivermectin that killed 50% (LC50), 25% (LC25) and 5% (LC5) of mosquitoes. To examine ivermectin sporontocidal effect, *Plasmodium vivax* blood samples were collected from malaria patients and offered to mosquitoes without or with ivermectin at the LC50, LC25 or LC5. To assess ivermectin inhibition of mosquito time to re-feed, concentrations of ivermectin predicted to occur after a single oral dose of 200 μg/kg ivermectin were fed to *An. darlingi*. Every day for 12 days thereafter, individual mosquitoes were given the opportunity to re-feed on a volunteer. Any mosquitoes that re-blood fed or died were removed from the study.

**Results:** Ivermectin significantly reduced *An. darlingi* survivorship: 7-day-LC50 = 43.2 ng/ml [37.5, 48.6], -LC25 = 27.8 ng/ml [20.4, 32.9] and -LC5 = 14.8 ng/ml [7.9, 20.2]. Ivermectin compound was sporontocidal to *P. vivax* in *An. darlingi* at the LC50 and LC25 Concentrations reducing prevalence by 22.6 and 17.1%, respectively, but not at the LC5. Oocyst intensity was not altered at any concentration. Ivermectin significantly delayed time to re-feed at the 4-h (48.7 ng/ml) and 12-h (26.9 ng/ml) concentrations but not 36-h (10.6 ng/ml) or 60-h (6.3 ng/ml).

**Conclusions:** Ivermectin is lethal to *An. darlingi*, modestly inhibits sporogony of *P. vivax*, and delays time to re-feed at concentrations found in humans up to 12 h post drug ingestion. The LC50 value suggests that a higher than standard dose (400-μg/kg) is necessary to target *An. darlingi*. These results suggest that ivermectin MDA has potential in the Amazon region to aid malaria elimination efforts.

**Keywords:** Ivermectin, *Anopheles darlingi*, *Plasmodium vivax*, Amazon
Background
Malaria incidence is declining globally and rates are falling in South America. Increased malaria control measures and access to effective artemisinin combination therapy for Plasmodium falciparum are attributed to this reduction, with Plasmodium vivax now being more prevalent than P. falciparum in the Americas, including the Amazon region [1, 2]. Anopheles darlingi is considered the primary malaria vector in the Amazon region [3]. Vector control is complicated by the exophagic and exophilic tendencies of An. darlingi combined with the fact that it typically occurs in recently cleared areas of the jungle where people may have limited access to vector control measures and health care [4–8]. Therefore, developing novel vector control strategies which can target exophagic and exophilic malaria vectors such as An. darlingi is essential to malaria elimination efforts in South America.

Numerous laboratory studies [9, 10], animal studies, and clinical trials [11, 12] have demonstrated that ivermectin is lethal to more than a dozen species of Anopheles worldwide. Ivermectin mass drug administration (MDA) has been suggested as a possible malaria parasite transmission control tool as it directly targets the vector at the point of human blood feeding, making it one of the few vector control tools under investigation that can directly target outdoor malaria transmission. Ivermectin MDAs in West Africa [13, 14] and the South Pacific [15, 16] validated that ivermectin is lethal to wild Anopheles at human-relevant concentrations. Furthermore, the ivermectin MDAs in Senegal, Liberia and Burkina Faso demonstrated that ivermectin can suppress P. falciparum transmission by wild Anopheles gambiae s.l. [14, 17]. In addition to mosquito-lethal effects, ivermectin at mosquito-sub-lethal concentrations affects additional parameters of vectorial capacity by inhibiting Plasmodium development in the vector [9, 18, 19] and delaying mosquito time to re-feed [20].

Ivermectin MDA campaigns have been performed in Central and South America for onchocerciasis elimination efforts by the Onchocerciasis Elimination Programme for the Americas (OEPA). These MDAs have been very effective at reducing Onchocerca volvulus transmission and have now eliminated the parasite from 11 of the 13 original foci [21–25]. Initially ivermectin MDAs for onchocerciasis were performed once or twice per year in Latin America. Later, it was determined that ivermectin could be given safely every 3 months [26] with quarterly MDAs effectively reducing transmission burden when nearing elimination [27]. Policy was changed and ivermectin MDAs have been deployed up to four times annually at various onchocerciasis elimination foci in Latin America [21]. This illustrates that frequent ivermectin MDAs with effective population coverage can be orchestrated in Latin America, and suggests that the more frequent ivermectin MDAs required to suppress malaria transmission [28] could be possible.

Before ivermectin MDAs for malaria parasite transmission suppression can be implemented in Latin America, the effects of ivermectin on key malaria vectors in the region, such as An. darlingi, must be evaluated. Laboratory studies were conducted to investigate the effect of ivermectin compound on An. darlingi survivorship, P. vivax development in An. darlingi and whether ivermectin delays the An. darlingi time to re-feed.

Methods
Mosquitoes
All An. darlingi were reared at the Naval Medical Research Unit No. 6 (NAMRU-6) in Iquitos, Peru as described previously [29]. Larvae were raised in the larvae insectary room (26.8 ± 0.7 °C and 76.1 ± 6.3% relative humidity, and 12-h light:12-h dark photoperiod) and adults were maintained in the adult insectary room (25.9 ± 0.8 °C and 69.7 ± 5.7% relative humidity, and 12-h light:12-h dark photoperiod). Adult mosquitoes used for experiments were provided with 10% sucrose solution ad libitum. Mosquitoes used for experiments were between 3 and 5 days post emergence and mosquitoes were sugar starved with access to water from 18 to 22 h prior to their first blood meal.

Drug
Ivermectin was prepared as described previously [9]. Powdered formulation of ivermectin compound was obtained from Sigma-Aldrich (St. Louis, MO, USA). Ivermectin was dissolved in dimethylsulfoxide (DMSO) to concentrations of 10 mg/ml and 20 µl aliquots were frozen at – 20 °C. Ivermectin was thawed and serial dilutions were made in phosphate buffered saline (PBS) and 10 µl was added to 990 µl of blood to reach final concentration desired for mosquito membrane-feeding assays. Control blood meals consisted of previously frozen DMSO diluted in PBS to match the ratio of DMSO and PBS fed to mosquitoes in the ivermectin-containing blood meals.

Blood
Chicken blood to maintain the mosquito colonies was obtained from a local slaughter-house consistent with previous studies [29]. Blood for lethal concentration calculation experiments were drawn from healthy volunteers and malaria-infected patients into 10 ml sodium heparin tubes (NH) (158 USP units, BD Vacutainer, Franklin Lakes, NJ, USA). Blood for lethal concentration experiments was stored at 4 °C and never more than 2 weeks post collection at the time of mosquito blood feeds. Plasmodium vivax-infected patients were identified by microscopic examination of Giemsa-stained thick blood smears at Ministry of Health health centres and hospitals in Iquitos. Patients were transported to NAMRU-6, enrolled and venous blood (15-ml) was drawn on site for the ivermectin sporogony
experiments following procedures approved by NAMRU-6 and Walter Reed Army Institute of Research Institutional Review Boards (NMRC.2008.0004 and WRAIR#2175) in compliance with all applicable Federal regulations governing the protection of human subjects. Blood for the ivermectin re-feeding experiments was collected from four healthy, non-malarious volunteers, as determined by microscopy and confirmed by a pre-optimized nested PCR assay [30, 31] (NAMRU6.2014.0009 and WRAIR#2342).

Ivermectin lethal concentration calculations
Lethal concentration calculations for An. darlingi were performed as described previously [9]. Anopheles darlingi were blood fed multiple concentrations of ivermectin to determine the lethal concentration that killed 50% (LC₅₀), 25% (LC₂₅) and 5% (LC₅) of the mosquitoes following previous methods [18, 20]. Control blood meals consisted of DMSO diluted in PBS to match the concentration found in the highest ivermectin treatment group in each replicate. After blood feeding via a membrane feeder, blood-fed mosquitoes were gently aspirated from the feeding container and transferred to clean, 250-ml, cardboard containers with access to 10% sucrose and kept in the infection insectary room at 24.8 ± 1.0 °C and 62.1 ± 6.7% relative humidity, on a 12-h light:12-h dark photoperiod. Mosquito survivorship was monitored for 7 days, every 24 h dead mosquitoes were removed and recorded. Volunteers returned to NAMRU-6 for 12 consecutive days for mosquito re-feeding opportunities. Any mosquitoes alive at the end of the experiment were recorded (NAMRU6.2014.0009 and WRAIR#2342).

Statistical analysis
Mosquito survival and sporontocidal results were analyzed as described previously [9]. A non-linear mixed effects model with Probit analysis was used to calculate 7-day-LC₅₀, -LC₂₅ and -LC₅ values with Statistical Analysis Software (SAS Institute, Inc., Cary, NC, USA) [20]. Hazard ratios for mosquito mortality at day 7 post-blood meal were calculated using Poisson regression analysis with STATA version 12.1 (Stata Corp. LLC, College Station, TX, USA). Oocyst prevalence (i.e., proportion of infected mosquitoes) was compared by Fisher’s Exact test. Oocyst intensity (i.e., number of oocysts per infected mosquito) was compared by the Mann–Whitney U test.

In the re-feeding experiment, mosquitoes that died instead of re-blood feeding, or survived to the end of the 12 days were censored data (up-ticks marked on each graph line). Replicates were pooled and analysed by the Logrank Test (Mantel–Cox method; proportional hazards model) and the hazard ratio with 95% confidence intervals. The Fisher’s Exact, Mann–Whitney U, and Logrank test analyses were performed with Prism 7 (GraphPad Software, Inc, San Diego, CA, USA).

Results
Ivermectin lethal concentration calculations
A total of 6161 mosquitoes and 13 replicates were used to calculate the lethal concentration of ivermectin. The
An. darlingi ivomectin lethal concentrations and 95% fiducial limits were estimated at day 7 as: LC50 = 43.2 ng/ml [37.5, 48.6], LC25 = 27.8 ng/ml [20.4, 32.9], and LC5 = 14.8 ng/ml [7.9, 20.2]. All ivomectin concentrations had significantly increased hazard of mortality compared to the control group except for 15, 12, 10, 8, and 4 ng/ml, while 12, 8 and 4 ng/ml had significantly reduced hazard for mortality (Table 1).

**Effect of ivomectin on Plasmodium vivax sporogony**

When ivomectin and *P. vivax* were co-ingested by *An. darlingi* it reduced oocyst prevalence at the ivomectin LC50 by 22.6% (χ² = 10.32, P = 0.0014, reps = 7, n = 287) and LC25 by 17.1% (χ² = 5.16, P = 0.0314, reps = 7, n = 285), and increased oocyst prevalence but not significantly at the LC5 by 11.3% (χ² = 1.95, P = 0.1918, reps = 7, n = 283) (Fig. 2). Mean oocyst intensity was reduced slightly at the LC50 by 2.3% (P = 0.6914, reps = 7, n = 196), increased at the LC25 by 37.3% (P = 0.1838, reps = 7, n = 194), and was reduced slightly at the LC5 by 4.6% (P = 0.8595, reps = 7, n = 200) (Fig. 3) but none of these trends was significant.

**Ivermectin inhibition of time to re-feed**

The ivomectin concentrations used for the re-feeding experiment were estimated from a previous clinical trial [32] at 4-h = 48.7 ng/ml, 12-h = 26.9 ng/ml, 36-h = 10.6 ng/ml, and 60-h = 6.3 ng/ml. The time to re-feed was delayed in *An. darlingi* that ingested the 4-h (48.7 ng/ml) (χ² = 10.11, P = 0.0015, HR = 2.961 [1.631–5.377], n = 287) and 12-h (26.9 ng/ml) (χ² = 6.072, P = 0.0137, HR = 1.987 [1.154–3.422], n = 151), but was not delayed following ingestion of 36-h (10.6 ng/ml) (χ² = 0.469, P = 0.4935, HR = 1.043 [0.646–1.684], n = 156), nor 60-h (6.3 ng/ml) (χ² = 1.502, P = 0.2203, HR = 1.355 [0.817–2.248], n = 145) (Fig. 4).

**Discussion**

These findings indicate that the primary Amazonian malaria vector, *An. darlingi*, is susceptible to ivomectin compound at human-relevant concentrations (Fig. 1). The *An. darlingi* ivomectin 7-day-LC50 = 43.2 ng/ml is roughly equal to another South American malaria vector, *Anopheles aquasalis* 5-day-LC50 = 47.0 ng/ml [10]. This demonstrates that ivomectin can alter the most influential variable for vectorial capacity, the daily probability of adult survivorship [33], in two important malaria vectors in South America. Recent ivomectin pharmacokinetic modelling [9] suggests that the 400-µg/kg dose may be the ideal minimal MDA dose to target both *An. darlingi* and *An. aquasalis* in South America. Ivomectin at the 400-µg/kg dose is now recommended in some instances for lymphatic filariasis MDA [34], and repeated doses every 2 weeks for 12 weeks were shown to be well tolerated in a trial in Brazil [35] and Sri Lanka [36].

The sporontocidal effect of ivomectin compound against *P. vivax* in *An. darlingi* significantly, albeit modestly, reduced oocyst prevalence at the LC50 and LC25 but not the LC5 (Fig. 2) and did not reduce oocyst intensity at any concentration (Fig. 3). This is surprising when compared to recent sporontocidal results of ivomectin against *P. vivax* oocyst prevalence and intensity reductions at the LC25 and LC5 in *Anopheles dirus* and *Anopheles minimus* [9]. Serum replacement from malaria naïve donors was not performed in the current study with *An. darlingi*, which may explain some of the differences in ivomectin sporontocidal effect observed between studies with *P. vivax*. Previously, ivomectin LC25 was shown to be sporontocidal against cultured *P. falciparum* NF54 in *An. gambiae*, reducing oocyst prevalence but not intensity [18, 19]. Differences in ivomectin sporontocidal effect may be partially explained by differences in vector biology and physiology as *An. darlingi* belongs to the New World *Nyssor琉璃us* subgenus while *An. dirus*, *An. minimus*, and *An. gambiae* belong to the *Cellia* subgenus. There is a shorter co-evolutionary history between *P. vivax* and New World *Anopheles*, when the parasite was possibly introduced from southern Asia in pre-Columbian times or from Europe in post-Columbian times [37]. It may be that these different vectors have different rates of peritrophic matrix formation which can be impacted by ivomectin [18] or different microbiota present in the colonized mosquitoes which could possibly be affected.

### Table 1 Hazard of mosquito mortality post ivomectin blood meal

| Conc. | IRR  | [95% CI] | P value |
|-------|------|---------|---------|
| 70    | 5.7  | [4.2–7.7] | < 0.0001 |
| 65    | 5.0  | [3.8–6.4] | < 0.0001 |
| 60    | 4.7  | [3.6–6.1] | < 0.0001 |
| 50    | 4.1  | [3.3–5.0] | < 0.0001 |
| 45    | 2.6  | [2.0–3.4] | < 0.0001 |
| 40    | 3.0  | [2.4–3.7] | < 0.0001 |
| 35    | 2.1  | [1.6–2.7] | < 0.0001 |
| 30    | 2.4  | [1.9–3.1] | < 0.0001 |
| 25    | 2.0  | [1.4–2.8] | < 0.0001 |
| 20    | 1.6  | [1.3–2.1] | < 0.0001 |
| 15    | 1.2  | [0.9–1.6] | 0.27    |
| 12    | 0.5  | [0.3–0.9] | 0.018   |
| 10    | 0.9  | [0.6–1.3] | 0.567   |
| 8     | 0.4  | [0.2–0.7] | 0.004   |
| 4     | 0.4  | [0.2–0.7] | 0.002   |

Conc. concentration of ivomectin imbibed in ng/ml, IRR incidence rate ratio of mortality at day 7 between each treatment group divided by the control group. 95% CI 95% confidence intervals

Significant P values (P < 0.05) are in italic
Ivermectin significantly delayed the time to re-feed for *An. darlingi* at the 4- and 12-h concentrations but not at the 36- or 60-h concentrations (Fig. 4). The time to re-feed is the second-most important variable in vectorial capacity, thus any delay at sub-lethal concentrations has ability to suppress transmission in the field [33]. Furthermore, a delay in *An. darlingi* time to re-feed may decrease the likelihood of survival which would compound mortality and further suppress *Plasmodium* transmission in the Amazon. A similar delay in time to re-feed after ivermectin ingestion was observed for *An. gambiae* [20], which may be caused by the ivermectin knockdown and delay in recovery effects also observed in *An. gambiae* [38].

The mechanism of action for ivermectin to delay *Anopheles* time to re-feed has not been characterized. Interestingly, it was demonstrated in the dung beetle, *Scarabaeus cicatricosus*, that ivermectin ingestion in dung diet decreased olfactory response and locomotor function, suggesting a negative impact on insect basic biological activities, such as food or mate-seeking [39]. In *An. gambiae*, the glutamate-gated chloride ion channel, which is the target of ivermectin, was found in the thoracic ganglia, Johnston’s organ, antennal segments, optic lobe and supraesophageal ganglion [40]. The thoracic ganglia contain motor neurons for regulating locomotor function of flight and leg muscles while the Johnston’s organ regulates flight coordination, which may explain the paralytic effect frequently observed following ivermectin ingestion by mosquitoes [38, 40]. The antenna, optic lobe and supraesophageal ganglion work in concert to regulate chemosensory and visual cues for host location, thus ingestion of ivermectin may impair the ability of mosquitoes to locate their host [40]. Moreover, reduced olfactory sensitivity towards ivermectin-treated animal host cues was recorded in the midge *Culicoides imicola* [41], further suggesting that ivermectin could inhibit host attraction and biting in haematophagous insects. Electroantennogram studies characterizing electrophysiological responses to host odour stimuli have not
be performed in Anopheles that have ingested ivermectin. If insect olfactory detection mechanisms or other sensory capacities are impacted by ivermectin, then this will inhibit the ability of Anopheles to detect vertebrates when host-seeking, which could delay time to re-feed. Ivermectin MDA campaigns conducted by OEPA demonstrate that repeated MDAs in Latin America are feasible at up to 3 month intervals. While the remoteness of some villages in the Amazon will make them difficult to contact, the successes being noted with ivermectin MDA in Yanomami indigenous populations in the Venezuelan Amazon are quite laudable [42]. Many people in areas of Latin America afflicted with malaria will likely have concomitant infections with numerous neglected tropical diseases (NTDs) that can be controlled with ivermectin such as lice, scabies, cutaneous larval migrans (CLM) [43], the soil-transmitted helminths (STHs) (e.g., Ascaris, Trichuris, and hookworm) [44, 45], and strongyloidiasis [46]. The OEPA once yearly ivermectin MDA reduced Strongyloides and Trichuris prevalence, but not Ascaris or hookworm in Ecuador [47] and Colombia [48]. Indeed, ivermectin can be quite effective against lice, scabies, CLM, STHs and strongyloidiasis when administered once [49] or twice within 7–10 days [50–52] and MDAs can be quite effective [51, 52]. However, re-infection from the soil for CLM, STHs and Strongyloides, and re-infestation from untreated persons for scabies and lice can occur quickly [52]. This suggests that more frequent ivermectin MDAs to target malaria parasite transmission could have dramatic impact on numerous NTDs found in Latin America, and may improve compliance with MDAs for malaria control.

Plasmodium vivax has become the most prevalent malaria species in Latin America. Due to the relapsing nature and inability to identify persons with P. vivax hypnozoites, this species will be considerably more difficult to eliminate. Several field trials are under way to eliminate P. falciparum by administering MDAs with dihydroartemisinin–piperaquine and low-dose primaquine [53, 54]. It has been observed that persons infected with P. falciparum also have dormant P. vivax hypnozoites that release after P. falciparum treatment [55–58]. Dihydroartemisinin–piperaquine is effective against blood stage P. vivax and the long half-life of piperaquine with once a month administrations can effectively suppress the frequent tropical P. vivax relapses at the blood stage [59]. Primaquine MDAs with the target of radical cure of P. vivax hypnozoites have been performed in several countries including: Afghanistan, Azerbaijan, Tajikistan, North Korea [60], Taiwan, Papua New Guinea, Solomon Islands, Tanzania, Nicaragua, Malaysia, Indonesia, China, Kyrgyzstan [61], Vanuatu [62], and Cambodia [63]. Since the total cumulative dose of primaquine provides radical cure of P. vivax hypnozoites [64] it is possible to space the primaquine MDAs every 7 [62] to 10 [63] days over several months. Ivermectin could be co-administered with primaquine MDAs every 7–10 days to achieve substantial suppression by Anopheles vectors for all Plasmodium species while specifically targeting P. vivax radical cure. Currently, clinical trials to investigate the safety and tolerability of ivermectin plus dihydroartemisinin–piperaquine (NCT02568098) [65] and ivermectin plus primaquine (NCT02568098) are being conducted. If ivermectin can be safely co-administered with anti-malarial drugs during MDAs, then this has the potential to be a powerful malaria and vector control intervention in Latin America.
Conclusions
Ivermectin reduces An. darlingi survivorship, modestly inhibits development of P. vivax in the vector by reducing oocyst prevalence at the LC50 and LC25 but not intensity, and delays time to re-feed at human-relevant concentrations up to 12 h post drug ingestion. The ivermectin 400-µg/kg dose is likely the ideal minimal dose used during ivermectin MDA in Latin America. The success of the OEPA against onchocerciasis indicates that ivermectin MDAs can be effectively executed in Latin America. Numerous NTDs that are prevalent in Latin America could be affected by ivermectin MDAs. This suggests that ivermectin MDAs could be a powerful new tool to aid malaria elimination in Latin America and would likely be well received as a public health measure.

Abbreviations
CLMs: cutaneous larval migrans; DMSO: dimethylsulfoxide; MDA: mass drug administration; NAMRU-6: Naval Medical Research Unit No. 6; NTDs: neglected tropical diseases; OEPA: Onchocerciasis Elimination Programme for the Americas; PBS: phosphate-buffered saline; STHs: soil-transmitted helminths.

Authors’ contributions
KK, KSE-V, VML-S and GMV designed experiments; KSE-V and VML-S conducted the experiments; KK and GMV analysed data; GMV, CAS, GCB, RVG and S-BB provided reagents; KK, KSE-V, VML-S, SO, ESS, GCB, RVG, S-BB, CAS and GMV wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Entomology, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. 2 Entomology Branch, Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver Spring, MD 20910, USA. 3 Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St., Rm. W5515, Baltimore, MD 21205, USA.

Acknowledgements
We thank all P. vivax-infected and healthy blood donors. We would like to acknowledge the help of the NAMRU-6 Departments of Entomology, Parasitology, and Virology staff, especially Drs. Christian Syles and Isabel Bazan for healthy volunteer enrollment and clinical evaluation; Miguel Vasquez, Geidin Chavez, Hugo Jaba, Luz Romero and Maria Bosantes for mosquito colony rearing, May Tello, Marlene Rios, Ericka Pinedo and Neyvis Cabrera for malaria patient enrollment, and Dolores Rimarchain, Grey's Braga, and Leonila Ricopa for vivax malaria diagnosis confirmation. We thank Dr. Kesara Na-Bangchang for kindly providing the ivermectin data used to predict concentrations to feed mosquitoes in the re-feeding experiment. This work was performed while Kevin Kobyliński held a National Research Council Fellowship. This work was supported by Grant OPP1095931 from the Bill & Melinda Gates Foundation.

Competing interests
The authors declare that they have no competing interests.

Copyright statement
Some authors of this manuscript are military service members and employees of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this Title is not available for any work of the United States Government.” Title 17 U.S.C. §101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties.

Disclaimer
The views, opinions, or assertions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of the Army, Department of Defense, nor the US Government.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Vitor-Silva S, Siqueira A, Sampaio V, Guinovart C, Reyes-Lecca R, Melo G, et al. Declining malaria transmission in rural Amazon: changing epidemiology and challenges to achieve elimination. Malar J. 2016;15:266.
2. WHO. World malaria report 2016. Geneva: World Health Organization; 2016.
3. Sinta M, Rubio-Palis Y, Manguin S, Patil A, Templeker W, Gething P, et al. The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic précis. Parasites Vectors. 2010;3:72.
4. Giroud R, Gaborn P, Carinci R, Issaly J, Fouque F. Anopheles darlingi bionomics and transmission of Plasmodium falciiparum, Plasmodium vivax and Plasmodium malariae in Amazonian villages of the Upper-Maroni Amazonian forest, French Guiana. Mem Inst Oswaldo Cruz. 2008;103:702–10.
5. Moreno J, Rubio-Palis Y, Páez E, Pérez E, Sánchez V. Abundance, biting behaviour and parous rate of anopheline mosquito species in relation to malaria incidence in gold-mining areas of southern Venezuela. Med Vet Entomol. 2007;21:339–49.
6. Hiwat H, Biretta G. Ecology of Anopheles darlingi root with respect to vector importance: a review. Parasites Vectors. 2011;4:177.
7. Moutinho P, Gill L, Cruz R, Ribolla P. Population dynamics, structure and behavior of Anopheles darlingi in a rural settlement in the Amazon rainforest of Acre, Brazil. Malar J. 2011;10:174.
8. Gill L, Alves F, Zierer H, Salcedo J, Durlacher R, Cunha R, et al. Seasonal malaria transmission and variation of anopheline density in two distinct endemic areas in Brazilian Amazonia. J Med Entomol. 2003;40:636–41.
9. Kobyliński K, Ubalee R, Ponlawat A, Nitatsukprasert C, Phasomkulsil S, Wattanakul T, et al. Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. Malar J. 2017;16:280.
10. Sampaio V, Beltrán T, Kobyliński K, Melo G, Lima J, Silva S, et al. Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector. Malar J. 2016;15:491.
11. Chaccour C, Rabinovich N, Slater H, Canavati S, Bousema T, Lacerda M, et al. Establishment of the ivermectin research for malaria elimination network: updating the research agenda. Malar J. 2015;14:243.
12. Chaccour C, Kobyliński K, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
13. Sylla M, Kobyliński K, Gray M, Chapman P, Sarr M, Rasong J, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.
14. Alout H, Krajacich B, Meyers J, Grubaugh N, Brackney D, Kobyliński K, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.
15. Bockarie M, Hii J, Alexander N, Bockarie F, Dagoro H, Kazura J, et al. Mass treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival. Med Vet Entomol. 1999;13:120–3.
16. Kositz C, Talina J, Diaj J, Augeneri R, Whitehorn C, Mabey D, et al. Incidental taeniascolical effect of an ivermectin mass drug administration on *Anoplocephala mearni* conducted for scabies control in the Solomon Islands. Trans R Soc Trop Med Hyg. 2017;111:97–101.

17. Kobylinski K, Sylva M, Chapman P, Sant M. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3–5.

18. Kobylinski K, Foy B, Richardson J. Ivermectin inhibits the sporogony of *Anopheles gambiae* in *Anopheles gambiae* (Diptera: Culicidae). J Exp Biol. 2015;218:1478–86.

19. Solli G, Solari P, Masaia C, Crnjar R, Liscia A. Effects of avermectins on olfactory responses of *Culicoides imicola* (Diptera: Ceratopogonidae). J Med Entomol. 2007;44:656–9.

20. Butters M, Kobylinski K, Deus K, da Silva I, Gray M, Sylva M, et al. Comparative evaluation of systemic drugs for their effects against *Anopheles gambiae*. Acta Trop. 2012;121:34–43.

21. Verdu J, Cortez V, Ortiz A, Gonzalez-Rodriguez E, Martinez-Pinna J, Lunaret J-P, et al. Low doses of ivermectin cause sensory and locomotor disorders in dung beetles. Sci Rep. 2015;5:13912.

22. Meyers J, Gray M, Kuklininski W, Johnson L, Snow C, Black W, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from *Anopheles gambiae*. J Exp Biol. 2015;218:1478–86.

23. Rodriguez-Pérez M, Fernández-Santos N, Orozco-Algarra M, Rodríguez-Morales K, et al. Elimination of onchocerciasis from Mexico. PLoS Negl Trop Dis. 2015;9:0003922.

24. Cabrada M, Lopez M, Arce E, Clinton WA. Prevalence of soil-transmitted helminths after mass albendazole administration in an indigenous community of the Manu jungle in Peru. Pathog Glob Health. 2014;108:200–5.

25. Valverde J, Gomes-Silva A, de Carvalho Moreira C, Leles de Souza D, Jaeger L, Martins P, et al. Prevalence and epidemiology of intestinal parasitism, as revealed by three distinct techniques in an endemic area in the Brazilian Amazon. Am Trop Med Parasitol. 2011;10:413–24.

26. Buonfrate D, Mena M, Angeheben A, Requena-Mendez A, Muñoz J, Bobbi F, et al. Prevalence of strongyloidiasis in Latin America: a systematic review of the literature. Epidemiol Infect. 2015;143:452–60.

27. Anselmi M, Buonfrate D, Espinoza A, Prandi R, Marquez M, Bobbi M, et al. Mass administration of ivermectin for the elimination of onchocerciasis significantly reduced and maintained low the prevalence of *Strongyloides stercoralis* in Esmeraldas, Ecuador. PLoS Negl Trop Dis. 2015;9:0004150.

28. Knudso A, Ariza Y, López M, Fajardo O, Reyes P, Moncada L, et al. The effect of ivermectin on geoehelminth frequency (i.e. as used in the onchocerciasis control program in Colombia). Rev Salud Publica. 2012;14:481–94.

29. Schuster A, Leshafft H, Reichert F, Talhan S, de Oliveira S, Ignatius R, et al. Hookworm-related cutaneous larva migrans in Northern Brazil: resolution of clinical pathology after a single dose of ivermectin. Clin Infect Dis. 2013;57:1155–7.

30. Worth C, Heukelbach J, Fengler G, Walter B, Lienenfeld O, Hengge U, et al. Acute morbidity associated with scabies and other ectoparasites rapidly improves after treatment with ivermectin. Pediatr Dermatol. 2011;28:430–6.

31. Heukelbach J, Wilcke T, Winter B, de Oliveira F, Moura R, Harns G, et al. Efficacy of ivermectin in a patient population concomitantly infected with intestinal helminths and ectoparasites. Arzneimittelforschung. 2004;54:416–21.

32. Heukelbach J, Winter B, Wilcke T, Muehlen M, Albrecht S, De Oliveira F, et al. Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population. Bull World Health Organ. 2004;82:563–71.

33. von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther. 2015;13:715–30.

34. Eisele T, Bennett A, Silumbe K, Finn T, Chalwe V, Kamuliro M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214:1831–9.

35. Lin J, Bethell D, Tyner S, Loni C, Shah N, Saunders D, et al. *Plasmodium falciparum* gametocyte carriage is associated with subsequent *Plasmodium vivax* relapse after treatment. PLoS ONE. 2011;6:18176.

36. Douglas N, Nosten F, Ashley E, Phaphun L, van Vugt M, Singhhasivanon P, et al. *Plasmodium vivax* recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52:612–20.

37. Loaareasuwan S, White N, Bunnag D, Chittasarn S, Harinasuta T. High-rate of *Plasmodium vivax* relapse following treatment of falciparum-malaria in Thailand. Lancet. 1987;2:1025–7.

38. Smithuis F, Kyaw M, Poe O, Win T, Aung P, Do O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine
in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10:673–81.
59. Lwin K, Phyo A, Tarning J, Hanpitakpong W, Ashley E, Lee S, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin–piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother. 2012;56:1571–7.
60. Kondrashin A, Baranova A, Ashley E, Recht J, White N, Sergiev V. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.
61. Shanks D. Control and elimination of Plasmodium vivax. Adv Parasitol. 2012;80:301–41.
62. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Björkman A. Malaria eradication on islands. Lancet. 2000;356:1560–4.
63. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin–piperaquine. Malar J. 2010;5:3.
64. Leslie T, Mayan I, Mohammed N, Erasmus P, Kalczynski J, Whitty C, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS ONE. 2008;3:2861.
65. Smit M, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, et al. Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya. JMIR Res Protoc. 2016;5:213.